灯盏乙素衍生物的合成及其生物活性

目的为提高灯盏乙素的生物利用度,设计合成了一系列灯盏乙素衍生物,评价其抗脂质过氧化和抗肿瘤的生物活性。方法通过羟乙基化、羟丙基化、酯化反应合成了一系列灯盏乙素衍生物,采用生化法测试部分衍生物对小鼠脑脂质过氧化产物丙二醛(malondialdehyde,MDA)的抑制作用,采用台盼蓝法测试体外抑制白血病细胞HL-60生长活性。结果合成了13个灯盏乙素衍生物,其中7个为未见文献报道的新化合物,其结构经1H-NMR和MS确证;化合物1、13对MDA的抑制作用显著,6-9具有中等强度的抗肿瘤活性。结论灯盏乙素结构中的酚羟基是其抑制脂质过氧化产物MDA的活性基团,葡萄糖醛酸的6-位游离羧基能够增强抗肿瘤活性。     

靶向CDK4/6抑制剂水飞蓟宾衍生物的合成及抗肿瘤活性研究

本文借助计算机辅助设计,结合已上市的CDK4/6抑制剂活性片段构建药效团模型,设计合成了15个水飞蓟宾C-7位结构衍生物。经MS、¹³C NMR和¹H NMR谱图解析确认,15个化合物均为未见文献报道的新化合物。采用MTT法,对人肝癌细胞(HepG-2)进行了初步的体外抗肿瘤活性研究。实验结果表明,所有化合物均比母体水飞蓟宾的活性有提高,其中化合物I₁对人HepG-2细胞有一定的抑制作用,值得进一步研究。     

水飞蓟宾衍生物的设计合成及抗肿瘤活性研究

目的 设计合成一系列新型水飞蓟宾衍生物，进行生物活性测试及分子对接研究。方法 以天然产物水飞蓟宾为先导化合物，对其C-23位羟基进行结构修饰，设计合成新型水飞蓟宾衍生物；采用MTT法，用人肺癌细胞(A549)和乳腺癌细胞(MCF-7)进行初步体外抗肿瘤筛选；利用计算机辅助药物设计方法分析所合成化合物关键基团与靶蛋白的作用方式。结果 合成了12个未见文献报道的水飞蓟宾衍生物，结构均经¹H-NMR、¹³C-NMR及MS谱确证。活性测试结果表明，化合物Ⅰ₃、Ⅰ₅对肿瘤细胞的抑制活性与阳性对照药alpelisib相当。结论 经过结构修饰后的水飞蓟宾衍生物具有一定的抗肿瘤作用，值得进一步研究。     

芒果苷衍生物的合成及其PTP1B酶抑制活性研究

目的设计合成一系列芒果苷衍生物并进行体外蛋白酪氨酸磷酸酶1B（PTP1B）抑制活性实验。方法利用亲核取代反应在芒果苷上引入疏水苄基,设计合成8个新化合物4~11,采用比色法对化合物进行PTP1B抑制活性研究。结果设计合成的8个化合物对PTP1B酶都有一定的抑制作用。结论芒果苷衍生物的活性明显好于芒果苷本身的活性,苄基的对位取代活性要优于邻位和间位取代,且苄基上氯原子取代的衍生物要高于其它原子取代的化合物活性。     

PLK1抑制剂的设计、合成及抗肿瘤活性研究

目的 设计合成一类新型PLK1抑制剂,并测试其对PLK1激酶的抑制活性,探讨初步构效关系,为后续相关研究提供参考。方法 以化合物HBST145为基础,通过生物电子等排等方法,设计、合成新型PLK1抑制剂,分别采用均相时间分辨荧光法和CCK-8法测定化合物对PLK1激酶的抑制活性以及抗肿瘤细胞增殖活性。结果与结论共合成了10个新化合物,其结构均经ESI-MS和¹H-NMR确证。抑酶活性结果表明化合物5a～5d、5j对PLK1抑制活性的IC₅₀值分别为2.58、3.09、7.08、3.61、8.99 nmol·L^-1,活性优于化合物HBST145。目标化合物5a～5j对HL-60和THP-1细胞的抗增殖活性均明显提高,其中化合物5d的抗细胞增殖活性较好,可作为优选化合物进行深入研究。     

含有查尔酮侧链的二氢青蒿素衍生物的设计、合成及其抑制白血病细胞增殖活性作用

目的设计合成一系列含有查尔酮侧链的二氢青蒿素衍生物,提高二氢青蒿素对白血病细胞的生长抑制活性。方法将取代查尔酮及其类似物拼合到二氢青蒿素的C-10位,设计28个查尔酮取代二氢青蒿素衍生物。采用细胞计数法测定其对HL-60、P388和P388/Adr细胞的生长抑制作用。结果与结论合成了28个含有查尔酮侧链的二氢青蒿素衍生物,均为未见文献报道的新化合物,其结构均经1H-NMR、MS和IR确证。所有目标化合物对HL-60、P388和P388/Adr细胞都有不同程度的生长抑制作用,初步构效关系分析结果:青蒿芳香醚类化合物的抗增殖活性好于青蒿脂肪醚类化合物,取代查尔酮侧链中的α,β-不饱和酮结构并不是影响抗增殖活性的必需基团,双键还原和全部还原产物活性相当。化合物5d对HL-60细胞的生长抑制作用最强,化合物7a、7 c和7 e对HL-60、P388和P388/Adr细胞均表现出显著的生长抑制活性,值得深入研究。     

5''''-脱氧-5-氟胞苷类衍生物的合成及其抗肿瘤活性

目的 设计并合成具有抗肿瘤活性的5'-脱氧-5-氟胞苷类衍生物.方法 2',3'-O-二乙酰-5'-脱氧-5-氟胞苷在三氯氧磷存在下与1,2,4-三唑缩合得到1-(2',3'-O-二乙酰-5'-脱氧-β-D-呋喃核糖)-4-(1,2,4-三唑-1-基)-5-氟嘧啶-2-(1H)-酮(3),后者用不同的亲核基团取代核苷C-4位上的三唑基团,制备一系列含有烷基胺、烷氧基和脒基的5'-脱氧-5-氟胞苷类衍生物.结果 合成了15个未见报道的新化合物,化合物的结构经1H-NMR、FAB-MS及元素分析确证.结论 抗肿瘤活性测试表明,其中某些化合物的活性与对照药物卡培他滨相当,对肺癌、结肠癌、乳腺癌和肝癌细胞显示出较好的抑制活性.     

5′-脱氧-5-氟胞苷类衍生物的合成及其抗肿瘤活性

目的设计并合成具有抗肿瘤活性的5′-脱氧-5-氟胞苷类衍生物。方法2′,3′-O-二乙酰-5′-脱氧-5-氟胞苷在三氯氧磷存在下与1,2,4-三唑缩合得到1-(2′,3′-O-二乙酰-5′-脱氧-β-D-呋喃核糖)-4-(1,2,4-三唑-1-基)-5-氟嘧啶-2-(1H)-酮(3),后者用不同的亲核基团取代核苷C-4位上的三唑基团,制备一系列含有烷基胺、烷氧基和脒基的5′-脱氧-5-氟胞苷类衍生物。结果合成了15个未见报道的新化合物,化合物的结构经1H-NMR、FAB-MS及元素分析确证。结论抗肿瘤活性测试表明,其中某些化合物的活性与对照药物卡培他滨相当,对肺癌、结肠癌、乳腺癌和肝癌细胞显示出较好的抑制活性。     

5＇-脱氧-5-氟胞苷类衍生物的合成及其抗肿瘤活性

目的设计并合成具有抗肿瘤活性的5＇-脱氧-5-氟胞苷类衍生物。方法2＇,3＇-O-二乙酰-5＇-脱氧-5-氟胞苷在三氯氧磷存在下与1,2,4-三唑缩合得到1-（2＇,3＇-O-二乙酰-5＇-脱氧-β-D-呋喃核糖）-4-（1,2,4-三唑-1-基）-5-氟嘧啶-2-（1H）-酮（3）,后者用不同的亲核基团取代核苷C-4位上的三唑基团,制备一系列含有烷基胺、烷氧基和脒基的5＇-脱氧-5-氟胞苷类衍生物。结果合成了15个未见报道的新化合物,化合物的结构经1H-NMR、FAB-MS及元素分析确证。结论抗肿瘤活性测试表明,其中某些化合物的活性与对照药物卡培他滨相当,对肺癌、结肠癌、乳腺癌和肝癌细胞显示出较好的抑制活性。     

基于VEGFR靶点的齐墩果酸类似物合成及生物活性研究

目的 设计并合成一系列基于血管内皮生长因子受体(vascular endothelia growth factor receptor, VEGFR)靶点、具有抗肿瘤活性的齐墩果酸衍生物。方法 利用计算机辅助药物设计技术，将VEGFR与已知活性小分子进行模拟对接，解析靶蛋白发挥活性作用的关键氨基酸片段，确定能够和关键位点结合的活性基团。以天然产物齐墩果酸为母体，在其A环上引入活性基团，同时对其C-28位羧基进行酰胺化结构修饰。采用MTT法，选用VEGFR高表达的人癌HepG2和A549细胞进行初步体外抗肿瘤活性筛选。结果 合成了10个全新的齐墩果酸类似物，结构经MS、¹H-NMR、¹³C-NMR谱确证。分子模拟对接显示目标化合物与VEGFR有较好的结合能力。活性测试结果表明目标化合物对两种癌细胞的抑制活性均强于母体，化合物Ⅰ₄和Ⅱ₅对HepG2细胞显示出较强的抑制活性(IC₅₀值分别为5.21μmol·L^-1和10.07μmol·L^-1...     

Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors

2-(3',4',5'-Trimethoxybenzoyl)-3-amino-5-aryl/heteroaryl thiophene derivatives were synthesized and evaluated for antiproliferative activity, inhibition of tubulin polymerization, and cell cycle effects. SARs were elucidated with various substitutions on the aryl moiety 5-position of the thienyl ring. Substituents at the para-position of the 5-phenyl group showed antiproliferative activity in the order of F=CH(3) > OCH(3)=Br=NO(2) > CF(3)=I > OEt. Several of these compounds led to arrest of HL-60 cells in the G2/M phase of the cell cycle and induction of apoptosis.     

β-榄香烯氨基酸衍生物的合成及抗肿瘤活性

目的设计合成β-榄香烯氨基酸衍生物,并进行体外、体内抗肿瘤活性研究。方法采用烯丙位的氯代反应合成β-榄香烯氯代物,再与氨基酸甲酯反应合成目标化合物。采用磺酰罗丹明B(SRB)染色法测定目标化合物体外对肿瘤细胞增殖的抑制作用,以小鼠腋下移植瘤为模型进行体内抗肿瘤试验,考察化合物5h对Lew is肺癌LL/2、肝癌H22模型的抑制作用。结果共合成15个β-榄香烯氨基酸和β-榄香烯氨基酸甲酯衍生物,其中12个化合物未见文献报道,合成化合物的结构经红外光谱、核磁共振氢谱和质谱确证。大部分目标化合物对人癌细胞HL-60、HeLa、SGC-7901的IC50值低于β-榄香烯。体内试验结果显示,化合物5h对Lewis肺癌LL/2、肝癌H22的生长有显著抑制作用。结论在β-榄香烯结构中引入氨基酸或氨基酸甲酯结构片段有利于提高此类化合物的抗肿瘤活性。     

Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II

A number of 4'-O-demethylepipodophyllotoxin derivatives possessing various 4 beta-N-, 4 beta-O- or 4 beta-S-aromatic rings have been synthesized and evaluated for their inhibitory activity against the human DNA topoisomerase II as well as for their activity in causing cellular protein-linked DNA breakage. The results indicated, that for DNA topoisomerase II, a basic unsubstituted 4 beta-anilino moiety is structurally required for the enhanced activity. Substitution on this moiety with CN, COOCH3, COOC2H5, OH and COOCH3, OCH3, COCH3, CH2OH, OCH2O, OCH2CH2O, phenoxy, morpholino, NO2, and NH2 either at the para and/or the meta position yielded compounds which are as potent or more potent than etoposide. Substitution with COOC2H5 and OH at the ortho position afforded inactive compounds. Replacement of the aryl nitrogen with oxygen or sulfur gave compounds which are much less active or inactive. However, replacement of the phenyl ring with a pyridine nucleus furnished compounds which are as active or slightly more active than etoposide. There is a lack of correlation between the ability of these compounds in inhibiting DNA topoisomerase II and in causing protein-linked DNA breaks.     

Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids

beta,beta,beta',beta'-Tetrasubstituted, long-chain dioic acids of the general formula HOOC-C(XY)-C(R2)-Q-C-(R2)-C(XY)-COOH have been synthesized and evaluated as hypotriglyceridemic-hypocholesterolemic agents in rats and as antidiabetogenic agents in ob/ob diabetic mice. The free carboxyl function of analogues of the series was mandatory for their hypolipidemic-antidiabetogenic effect while nonhydrolyzable diesters were inactive. Other structure-activity relationships were determined as a function of the overall chain length (C12-C22), alpha,alpha'-substitutions (X, Y = H, F, Cl, Br, OH, CN), beta, beta'-substitutions (R = CH3, C6H5), and core substitutions [Q = (CH2)10, (CH2)4CH = CH(CH2)4, 1,4-C6H10[(CH2)3]2, 1,4-C6H4[(CH2)3]2, 1,4-C6H4(CH = CHCH2)2, CH2(OCH2CH2)3OCH2)]. The most effective hypolipidemic-antidiabetogenic members of the series were alpha,alpha'-nonsubstituted, beta,beta'-methyl-substituted analogues of 14-18-carbon chains having either a saturated aliphatic core or a 1,4-bis(propenyl)benzene core in the cis/trans configuration. The hypotriglyceridemic rather than the hypocholesterolemic capacity of members of the series was found to correlate with their respective capacities as liver peroxisomal proliferators in rats.     

N′-取代苯基-2-苯并噻唑磺酰脲类化合物的合成

目的为寻找具有抗肿瘤活性的新化合物,设计合成一系列N′-取代苯基-2-苯并噻唑磺酰脲类化合物。方法以2-巯基苯并噻唑为原料,经弱氧化、氨化、再氧化得到2-苯并噻唑磺酰胺;各种取代苯胺与三光气反应制得一系列取代苯异氰酸酯;2-苯并噻唑磺酰胺与各种取代苯异氰酸酯反应,得到一系列N′-取代苯基-2-苯并噻唑磺酰脲类化合物。结果与结论合成了15个N＇-取代苯基-2-苯并噻唑磺酰脲类化合物,除化合物6b外其余14个未见文献报道。目标化合物的结构均经承、1H-NMR和MS确证。初步体外活性筛选结果表明,目标化合物6b、6e、6n有一定的抗肿瘤活性,进一步的抗肿瘤活性测试正在进行中。     

3-取代-5-氟-1-2-二氢-3H-吲哚-2-酮类化合物的合成及抗肿瘤活性

5-溴-1H-吲哚经氰基取代、Vilsmeier-Haack反应、水解、缩合制得3-[(Z)-(5-氟-1,2-二氢-2-氧代-3H-亚吲哚基)甲基]-1H-吲哚-5-甲酸,再和相应的胺类化合物反应制得10个3-取代-5-氟-1,2-二氢-3H-吲哚-2-酮类化合物.以舒尼替尼为阳性对照,用MTT法测试目标化合物对人乳腺上皮细胞HMEC的体外抑制活性,其中1c、1f、1g和1h在浓度为10 μmol/L时,对HMEC的抑制活性优丁舒尼替尼.进一步测试1c和1e对SGC7901、A549、HL-60、SK-BR-3、HCT116肿瘤细胞株的抗增殖活性.结果表明,1c和1e对白血病细胞株HL-60的抗增殖活性优丁舒尼替尼.     

Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 2. Synthesis and estrogen receptor binding affinity of 4,4'-, 5,5'-, and 6,6'-disubstituted metahexestrols

The syntheses of symmetrically 4,4'-, 5,5'-, and 6,6'-disubstituted derivatives of the mammary tumor inhibiting antiestrogen metahexestrol [meso-3,4-bis(3-hydroxyphenyl)hexane] (1) are described [4,4'-substituents: F, (2), Cl (3), Br (4), I (5), CH2N (CH3)2 (6), CH3 (7), CH2OCH3 (8), CH2OC2H5 (9), CH2OH (10), NO2 (11), NH2 (12), N(CH3)2 (13), COCH3 (14), and C2H5 (15); 5,5'-substituents: OH (16) and Cl (17); 6,6'-substituents: OH (18), F (19), Cl (20), and CH3 (21)]. The synthesis of 1-3, 16, and 19 was accomplished by reductive coupling of the propiophenones with TiCl4 /Zn and subsequent hydrogenation of the cis-3,4- diphenylhex -3- enes . Compounds 17, 18, 20, and 21 were synthesized by coupling the 1-phenyl-1-propanols with TiCl3 /LiAlH4 and separation of the meso diastereomers, while 4-15 were obtained by substitution of metahexestrol . The binding affinity of these compounds to the calf uterine estrogen receptor was measured relative to that of [3H]estradiol by a competitive binding assay. The test compounds showed relative binding affinity (RBA) values between 15 and less than 0.01% that of estradiol. Only compound 21 showed an estrogen receptor binding affinity exceeding that of metahexestrol (15 and 10%, respectively). Compounds exhibiting RBA values of greater than 0.5% were evaluated in the mouse uterine weight test. They showed a similar (2 and 12), slightly increased (19 and 21), or strongly enhanced (7 and 20) estrogenicity compared to that of metahexestrol . Compounds 1, 2, 7, 12, and 21 exhibited antiestrogenic activity inhibiting the estrone-stimulated uterine growth (24 to 60% inhibition).     

Synthesis of a bifunctional coordination complex of osmium with curariform activity.

Based on the known curariform action of tris(bipyridyl)iron(II) sulfate and other complex ions, two series of bifunctional ligands designed to hold transition metal ions at approximately the same distance apart as the interquaternary ammonium distance in the potent neuromuscular block agents were synthesized. In the first series two 1,10-phenanthrolines (R1) were joined at the 2 position to form four compounds: R1CO-c-N(CH2CH2)2N-COR1, R1CONH-1,2-C6H10-NHCOR1, R1CONH-1,2-C6H4-NHCOR1, and R1CON(CH3)(CH2)2N(CH3)COR1. In the second series two terpyridines (R1) were joined by different chains to give R2(CH2)2CH=CH(CH2)2R2, R2CH2C(CH3)(OH)(CH2)2C(CH23)(OH)CH2R2, R2CH2C(CH3)(OH)C(CH3)(OH)CH2R2, and R2CH2(OH)-1,4-C6H10-(OH)CH2R2. Three other ligands in which the terpyridines were joined by 5-, 60, and 7-methylene groups were also made. The ligands were converted to nickel(II) complexes and the coordination of each nickel ion was completed by adding terpyridine. These were assayed by the intravenous mouse LD50 method. The most potent ligand, the di-hydroxy compound R2CH2(OH)-1,4-C6H10-(OH)CH2R2 was then converted to the bis(pyridinebipyridine)diosmium-(II) coordinated complex and assayed by the iv mouse LD50 method and by the ED50 isolated guinea-pig diaphragm method. By the iv mouse LD50 method, it was about twice as potent as d-tubocurarine and by the isolated diaphragm method, it was 16 times more potent. The compound has been called dihydroxyosmarine tetrachloride or DHO for short. The term "transarine" ions is proposed for transition metal coordination complexes having curariform action. The position of the transarine ions is discussed in the classification of cholinergic ligands, in structure-action relationships, and in relation to some current ideas on receptor mechanisms.